摘要
目的探讨索拉非尼治疗肝癌肝移植术后复发的疗效。方法 30例肝癌肝移植术后肿瘤复发患者,随机分为对照组和研究组,各15例。对照组在确诊肝癌肝移植术肿瘤复发后继续接受雷帕霉素免疫抑制方案,研究组在对照组治疗基础上加用索拉非尼。对比两组患者治疗前后甲胎蛋白(AFP)水平及确诊肿瘤复发后6个月生存情况。结果两组患者治疗前AFP水平比较差异无统计学意义(P>0.05);治疗后研究组AFP水平较对照组明显低,差异具有统计学意义(P<0.05)。研究组患者确诊肿瘤复发后6个月生存率为73.3%,明显高于对照组的33.3%,差异具有统计学意义(P<0.05)。结论索拉非尼可以延长肝癌肝移植术后复发患者的生存期。
Objective To investigate curative effect by sorafenib in the treatment of postoperative recurrence of liver cancer after liver transplantation. Methods A total of 30 patients with postoperative recurrence of liver cancer after liver transplantation were randomly divided into control group and research group, with 15 cases in each group. The control group received rapamycin immunosuppression regimen after recurrence of liver cancer, and the research group received additional sorafenib to rapamycin for treatment. Comparison was made on alpha fetoprotein（AFP） level before and after treatment and 6-month survival situation after diagnosed recurrence of tumor between the two groups. Results There was no statistically significant difference of AFP level between the two groups before treatment（P〉0.05）. After treatment the research group had obviously lower AFP level than the control group, and their difference had statistical significance（P〈0.05）. The research group had 6-month survival rate after diagnosed recurrence of tumor as 73.3%, which was much higher than 33.3% in the control group, and their difference had statistical significance（P〈0.05）. Conclusion Sorafenib can prolong survival period in patients with postoperative recurrence of liver cancer after liver transplantation.
出处
《中国实用医药》
2017年第8期121-123,共3页
China Practical Medicine
关键词
索拉非尼
肝癌
肝移植
复发
Sorafenib
Liver cancer
Liver transplantation
Recurrence
